Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 34 clinical trials
featured
A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

  • 82 views
  • 08 Nov, 2020
  • 1 location
featured
A Phase 3 Clinical Trial for Patients with Moderately to Severely Active Ulcerative Colitis

A Phase 3 Clinical Trial for Patients with Moderately to Severely Active Ulcerative Colitis

  • 170 views
  • 08 Nov, 2020
  • 1 location
featured
A Phase 3 Clinical Trial for Patients with Moderately to Severely Active Crohn's Disease.

A Phase 3 Clinical Trial for Patients with Moderately to Severely Active Crohn's Disease.

  • 274 views
  • 08 Nov, 2020
  • 1 location
featured
Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

  • 182 views
  • 23 Nov, 2020
  • 1 location
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

The purpose of this study is to evaluate the efficacy of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal

  • 42 views
  • 28 Oct, 2020
  • 113 locations
Defining Predictors of RT Response to Vedolizumab in IBD

The overall goal of the study is to develop data that can convincingly guide clinicians on the use and efficacy of vedolizumab in patients with small bowel CD. There is an unmet need to identify

  • 12 views
  • 24 Jan, 2021
  • 1 location
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

The purpose of this study is to assess the effect of vedolizumab intravenous IV as induction and maintenance treatment in Chinese participants with moderately to severely active ulcerative

  • 8 views
  • 01 Nov, 2020
  • 20 locations
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases

Vedolizumab (VDZ) is a humanized immunoglobulin G1 monoclonal antibody acting against 47 integrin which modulates lymphocyte trafficking in the gut. Results from the adult GEMINI-1 and

colitis
enteropathy
inflammatory bowel disease
ulcerative colitis
remission
  • 129 views
  • 22 Jan, 2021
  • 13 locations
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis

Phase IIb study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.

tumour necrosis
mesalamine
tumor necrosis factor alpha
methotrexate
antidiarrheals
  • 132 views
  • 24 Jan, 2021
  • 163 locations
Fecal Microbial Transplantation and Vedolizumab Treatment of Crohn's Disease

The investigators postulate that by determining a patient's baseline microbiome and manipulating it through fecal microbial transplantation (FMT) may improve response rates to vedolizumab in

vedolizumab
remission
crohn's disease
  • 10 views
  • 24 Jan, 2021
  • 2 locations